Rob Windsor

Rob Windsor currently serves as the Chief Business Officer at LifeSci Partners. Previously, Rob held the position of Head of Investor Relations at Seres Therapeutics and Sigilon Therapeutics, the latter of which was acquired by Eli Lilly in September 2023. Additionally, Rob has extensive experience in financial services, having worked as the Managing Director of Financial Software Sales at William O'Neil + Co., Inc. and as the Senior Vice President of Institutional Equity Sales at Jefferies.